What Innate Pharma’s Kempen conference participation reveals about its 2026 biotech strategy
Innate Pharma heads to Kempen as investors assess its oncology pipeline, partnering outlook, and next catalysts. Read the full analysis.
Amani Therapeutics bets $25m on expanding clozapine access in schizophrenia
Amani Therapeutics raises $25M to advance AM-01, a fixed-dose clozapine combination targeting neutropenia. Analysis of what changes — and what risks remain.
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start
Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves […]
What AstraZeneca’s KALOS and LOGOS data reveal about triple inhaler therapy in asthma
AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.
Is ENHERTU plus pertuzumab on track to redefine first-line treatment in HER2-positive metastatic breast cancer?
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.
What AstraZeneca’s C-CAR031 deal reveals about the future of CAR-T in liver cancer
AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.
Can Lynx Analytics’ Lumen framework reshape AI-driven decision-making in life sciences?
Lynx Analytics has introduced Lumen, a dedicated agentic artificial intelligence framework designed to support complex decision-making across life sciences workflows. The launch was anchored by a real-world deployment at AstraZeneca, where a custom-built application called IlluminAI is now embedded in the oncology team’s brand planning process across international markets. The framework is positioned as a […]
Illumina’s Billion Cell Atlas marks inflection point for AI-enabled drug discovery in 2026
Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks […]
AstraZeneca, Daiichi Sankyo push Enhertu into early breast cancer with new FDA nod
AstraZeneca PLC and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for use in patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment and are at high risk of recurrence. The designation is based on positive results […]
Beyond ovarian and breast cancer: Are PARP inhibitors finally proving their worth in urologic oncology?
The class of poly (ADP-ribose) polymerase inhibitors, once celebrated as a breakthrough in ovarian and breast cancer, has endured a reputation decline following safety concerns and regulatory rollbacks. But recent data suggest that prostate cancer, specifically metastatic castration-resistant prostate cancer with BRCA mutations, may offer PARP inhibitors a new lease on life. The December 2025 […]